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Effects of Chronic Use of Carbamazepine and Valproate 
on Cognitive Processes 
A. M. L. Coenen, G. M. L. G. Konings, 1A. P. Aldenkamp, 2W. O. Renier, and 
E. L. J. M. van Luijtelaar 
We investigated ffects on cognitive processes of chronic use of carbamaze- 
pine (CBZ) and valproate (VPA) in a group of young patients with epilepsy. ' 
Scores on various neuropsychological tests were obtained from patients 
treated with two monotherapy regimens, one involving CBZ and one involv- 
ing VPA. In general, the cognitive profile of the two antiepileptic drugs 
(AEDs) was the same, except for some attention and memory aspects on 
which the VPA subjects cored better and for some motor tests which the 
CBZ group performed faster. The latter finding is in accord with results of 
studies reporting an increase in motor speed induced by CBZ. Furthermore, 
the observed impairments caused by both CBZ and VPA were relatively mild 
as compared with those caused by traditional AEDs such as phenytoin (PHT) 
and phenobarbital (PB). Key Words: Carbamazepine--Valproate-- 
Cognition--Attention--Memory--Motor speed. 
Patients with epilepsy often show cognitive im- 
pairments; memory problems and disturbances of
attention and concentration are the most fre- 
quently reported isorders (1-4). The negative f- 
fects on cognition are attributed to factors uch as 
structural brain changes, type of seizures, fre- 
quency of seizures, and ictal discharges. Recently, 
Received April 1, 1994; accepted March 16, 1995. 
From the Department of Psychology, University of 
1 Nijmegen, Nijmegen, Department of Pediatrics, Uni- 
2 versity of Leiden, and Department of Child Neurology, 
University Hospital Nijmegen, Nijmegen, The Nether- 
lands. 
Address correspondence and reprint requests to Dr. 
A. M. L. Coenen at NICI, Department of Psychology, 
University of Nijmegen, P.O. Box 9104, 6500 HE Nij- 
megen, The Netherlands. 
however, the detrimental effects of antiepileptic 
drugs (AEDs) themselves have been emphasized 
(4-7); e.g., Andrewes et al. (8) reported that pa- 
tients treated with phenytoin (PHT) monotherapy 
performed worse on memory tests than patients 
treated with carbamazepine (CBZ) monotherapy. 
In addition, Corbett et al. (9) described a relation- 
ship between the duration of AED therapy and 
cognitive decline for various drugs, noting only 
slight effects for valproate (VPA). Trimble and 
Thompson (10) observed negative ffects on mem- 
ory for PHT, phenobarbital (PB), and ethosuxi- 
mide as compared with CBZ and VPA. Dam (11) 
attributed the negative ffects of the former drugs 
to their more serious side effects. 
In their review of the literature, the Committee 
on Drugs (12) concluded that CBZ and VPA should 
be considered first-choice medications. O'Dough- 
erty et al. (13), however, reported that CBZ pro- 
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duced impairments in short-term emory. Other 
evidence suggests that VPA also causes cognitive 
impairments (14-16). In accord with such findings 
Gallassi et al. (17,18) showed that discontinuation 
of AEDs is associated with a diminution in cogni- 
tive impairments. Moreover, a reduction in dose or 
a shift from polytherapy to monotherapy also 
causes cognitive improvements (7,19,20). Alden- 
kamp et al. (21) noted differential drug effects in a 
withdrawal study in children, showing that dis- 
continuation of PHT had more positive effects on 
cognition than did discontinuation f CBZ or VPA. 
Nevertheless, Coenen et al. (22) reported improve- 
ment of scores on cognitive tests due to the dis- 
continuation of CBZ as well as VPA. However, a 
direct comparison between the effects on cognition 
of CBZ and VPA has not yet been made. In this 
study, we investigated the cognitive profiles of 
these two first-choice medications in subjects 
treated either with CBZ or VPA as monotherapy. 
Methods  
In all, 19 patients with epilepsy, 5 young men 
and 14 young women, were recruited from three 
outpatient clinics located in three different regions 
of The Netherlands. The mean age of the patients 
was 16.2 years (range 12-22 years). The I.Q. of all 
subjects was >80, and all were from middle-class 
families. Epileptic seizures were not the conse- 
quence of cerebral esions in any participant, as 
shown by negative computed tomography (CT) or 
magnetic resonance imaging (MRI) scans, and ep- 
ileptic seizures were almost controlled, with a fre- 
quency of less than one seizure in 3 months. 
Matched on the basis of medication and for age 
and I.Q., subjects were divided into two groups: a 
CBZ (Tegretol) group (n = 11) and a VPA (Depa- 
kine) group (n = 8). Most patients (7 in the CBZ 
and 6 in the VPA group) had idiopathic general- 
ized epilepsy, and a minority (4 in the CBZ group 
and 2 in the VPA group) had symptomatic local- 
ization-related epilepsy. Consequently, despite 
general differences in prescription of the two 
AEDs, we concluded that no differences existed 
between the groups in type and frequency of epi- 
lepsy. Moreover, there were no differences in the 
duration of existence of epilepsy between groups, 
which in all cases was -5--6 years. The patients 
had also received AEDs for that time, and there 
were no changes in type of AED in that time. A 
matching criterion which could not be fully met 
was gender: All subjects in the VPA group were 
women. All relevant information about the pa- 
tients is shown in Table 1. 
All patients were tested in the morning for 2 h in 
a quiet room with minimal distraction. The test 
battery consisted of 10 tests measuring memory, 
attention, and concentration, aswell as psychomo- 
tor performance and motor speed. The tests were 
the following: first, the Raven Progressive Matrices 
test to assess I.Q. (23); second, the Trailmaking 
test with trail A and B, measuring psychomotor 
performance and mental and motor speed (24); 
third, the Complex Figure of Rey test for visuoper- 
Table 1. Composition of the two groups 
Group VPA CBZ 
No. of subjects 8 
M 0 
F 8 
Education 
Primary school 1 
Secondary school 7 
Type of epilepsy 
Idiopathic generalized epilepsy 6 
Localization-related epilepsy 2 
Age (yr) 15.7 -+ 
I.Q. 114.8 --- 
Duration of medication (yr) 4.7 - 
Daily drug dose (mg) 550 -+ 
Blood level of drug (~g/ml) 65.2 + 
11 
7 
4 
10 
7 
4 
2.7 16.1 +-- 2.9 
12.1 110.6 -+ 11.6 
2.9 6.7 + 4.6 
350 460 --- 295 
20.8 5.6 +-- 2.2 
VPA, valproate; CBZ, carbamazepine. 
Values are n or mean -+ SD. There were no differences between the 
groups with regard to age, I.Q., and medication duration. 
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ceptual organization and visual memory (25) (after 
patients copied this figure their delayed recall was 
tested after 15 min); and fourth, the Finger Tap- 
ping test, a motor task in which both the right and 
left hand were tested. A self-constructed version 
was used, containing a light-weight button which 
had to be pressed as many times as possible in 
10 s. After a 15-min interval, patients were given 
the remaining six tests. In the fifth test, the Bour- 
don Dot Cancellation Test for sustained attention 
and regularity in performance (26), groups of 3, 4, 
and 5 dots are presented, and configurations of 4 
dots had to be cancelled as quickly as possible. The 
sixth test was a simple reaction time test in which 
subjects had to push a button as fast as possible 
after the onset of a tone. In the seventh test, the 
15-Word test for auditory and verbal memory (25), 
lists of 15 words were presented five times, each 
with an immediate recall. The patients' delayed 
recall was tested after 20 min. The eighth test was 
the Stroop Color-Word test for selective and fo- 
cused attention (25,27). The ninth was the fluency 
test for mental organization and retrieval of long- 
term memory (24), tested in a semantic modality in 
which examples of the category "trees" had to be 
named. The last test was the pegboard test for psy- 
chomotor performance (24). 
After patients finished all tests, blood samples 
were taken to verify drug concentrations. Blood 
serum levels were within normal reference ranges: 
VPA subjects 65.8 + 20.2 ~g/ml (normal range 45- 
105 ~g/ml); CBZ subjects 5.6 - 2.2 ~g/ml (normal 
range 4-8 ~g/ml). No patient had either intoxica- 
tion levels or levels that were below normal. 
Results 
Differences between scores for the VPA and the 
CBZ groups were analyzed by a two-tailed t test 
for independent groups. All data are shown in Ta- 
ble 2. Statistically significant differences were 
noted in the attention tests. The Bourdon Dot Can- 
cellation test showed that the VPA group worked 
more regularly (they had smaller SDs) and more 
accurately (they missed fewer correct configura- 
tions). In the Stroop Color-Word test, subjects in 
the CBZ group reacted faster on card 1 and made 
more errors on reading card 3, the card with which 
interference is determined. With respect o the 
memory tests, the VPA group was significantly 
better in immediately recalling the total number of 
words after the word lists were presented three 
times. These differences decreased tomarginal sig- 
nificant levels in the fourth and fifth trials and, in 
accord with this, there were no further significant 
differences between the two groups in delayed re- 
call. 
We also noted a difference between the two 
groups on motor performance. On the tapping 
test, the CBZ group was superior in both-hands 
condition, significant for the right hand condition, 
and marginally significant for the left hand condi- 
tion. In the simple reaction time test, the CBZ 
group also tended to perform better, with faster 
reaction times. 
Discuss ion 
In several tests involving attention, the VPA 
group performed better than the CBZ group. Sub- 
jects in the latter group had more omissions in the 
Bourdon Dot Cancellation test and more errors in 
the Stroop Color-Word test. Furthermore, results 
from the cancellation test indicate that the VPA 
group worked with more regularity: they showed 
significantly smaller SDs in this test. Fluctuations 
in attention and concentration i the CBZ group 
probably led to omissions in this task. CBZ may 
exert a more negative influence on attention and 
concentration than VPA. In accord with this pos- 
sibility, Aman et al. (14) and Aldenkamp et al. 
(21,28) demonstrated that VPA provides more ef- 
fective protection against epileptiform activity. 
With VPA, then, it may be easier to maintain stable 
sustained attention because disruptive activity is 
absent, which might explain why VPA subjects 
also worked with more regularity. Furthermore, 
the CBZ group showed more inferior performance 
in tests that require memory function. Recall on 
the 15-word test in the early phase of learning was 
significantly poorer in the CBZ group, which is in 
accord with the finding in another field of research 
showing that the level of attention and the amount 
of memory consolidation are positively related 
(29). 
In contrast to the superior performance evident 
in strictly cognitive ffects of the VPA group, the 
CBZ group showed superior performance in tasks 
demanding pure motor speed. In the tapping task 
and in card I of the Stroop test, the CBZ group was 
superior in terms of speed measures. A similar ten- 
dency was evident in the simple reaction time task. 
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CBZ, VPA, AND COGNITION 
Means and SD of the various test scores of the VPA and 
CBZ groups 
Test VPA CBZ p-Value 
Attention 
Bourdon-Vos test 
Mean line time (s) 13.1 --- 2.6 12.2 - 2.2 0.41 
SD 0.6 --- 0.4 1.4 +-- 1.1 0.03 a 
Total time (min) 7.2 --- 1.4 6.7 -+ 1.2 0.40 
Omissions 1.6 --- 1.5 6.1 -+ 4.6 0.01 ~ 
Stroop test 
Time card 1 (s) 48.6 --- 5.0 43.4 -+ 5.7 0.05 a 
Time card 2 (s) 62.4 + 11.8 61.8 -+ 10.8 0.91 
Time card 3 (s) 95.1 --- 14.8 88.2 -+ 28.1 0.51 
Errors card 3 0.1 --- 0.4 1.8 +-- 1.8 0.01 a 
Trailmaking test 
Trail A (s) 32.4 + 8.1 30.2 --- 8.8 0.59 
Trail B (s) 42.4 --- 10.1 42.5 --+- 14.5 0.98 
Memory 
15-Word test (No. of words) 
Total recall 1-3 29.7 --- 4.2 25.5 -+ 4.5 0.05 ~ 
Total recall 1-5 55.1 --- 5.9 48.9 +- 8.8 0.08 
Delayed recall 12.3 -+ 2.5 10.5 -+ 2.9 0.19 
Figure of Rey test 
Score copy 35.9 --- 0.4 35.7 +-- 0.6 0.53 
Score recall 24.1 - 4.2 21.5 -+ 7.0 0.31 
Fluency test 
No. of items 8.8 --- 2.4 6.1 +-- 2.8 0.59 
Motor speed 
Finger tapping test (n/10 s) 
Left hand 48.0 -+ 7.2 55.8 +-- 10.5 0.07 
Right hand 51.3 -+ 9.3 67.1 +- 15.0 0.01 ~ 
Simple reaction time test 
Mean time (ms) 204.1 + 19.0 182.1 +- 40.9 0.15 
Pegboard test (s) 
Mean time left hand 9.0 -+ 0.5 9.3 -+ 0.9 0.42 
Mean time right hand 8.5 -+ 0.8 8.3 - 0.8 0.53 
VPA, valproate; CBZ, carbamazepine. 
ap < 0.05. 
These data are consistent with several reports, all 
indicating that CBZ increases motor speed (13,30- 
33). Our present findings also indicate that CBZ 
may have a positive influence on this parameter. 
Effects on speed, however,  are not always ob- 
served. Smith et al. (20) reported a study in which 
PB, PHT, primidone, and CBZ were compared. Al- 
though better test scores for the latter drug were 
obtained, no significant speed differences were de- 
tected. A possible explanation for these contradic- 
tory findings might be a differential effect of CBZ 
on pure motor speed and speed in which more 
mental processes, such as attention and concentra- 
tion, are involved. When mental speed or speed 
with fine motor performance or with eye-hand co- 
ordination is the more important factor in deter- 
mining overall performance, as in the trailmaking 
and the pegboard test, the speed measures might 
be different. For card 1 of the Stroop test, an al- 
most purely motor task that can be performed al- 
most automatically, significant differences existed 
between the two groups. On the other hand, no 
group differences were evident for card 3 and, to a 
minor degree, for card 2, cards for which consid- 
erable attention and mental speed is required. In 
these cases, the facilitating effects of CBZ are re- 
duced by the negative ffects on attention and the 
net effect is minor. This analysis indicates that a 
positive effect of CBZ may be restricted to motor 
speed rather than to cognitive function. Such a 
conclusion is only partially in accord with the 
claims for a psychotropic effect of CBZ (33-35). 
If the present results are viewed in light of the 
complex and sometimes conflicting data in the lit- 
erature, they suggest hat both CBZ and VPA may 
have negative effects on cognition. These effects 
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seem mild,  however ,  in  compar i son  to those of 
classic AEDs such as PHT or PB. The effects of 
both  drugs,  however ,  are found in di f ferent do- 
mains.  Pure motor  per formance  appears  to profit 
in some way  from CBZ as compared  with  VPA, but  
at tent ion  and  memory  are mi ld ly  affected by CBZ. 
On  the other hand,  a l though VPA does not  have 
such effects on  motor  per formance,  it has less neg-  
ative effects on  at tent ion  and  memory  than  CBZ. 
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